Cited by 874HER2/EGFR in Cancer ResearchLung Cancer Treatments and MutationsPI3K/AKT/mTOR signaling in cancer

The DOI matches its Crossref record; 73 of the 83 references it cites were found in a registry or an index.

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

Open access

Agus, David B, Akita, Robert W, Fox, William D, Lewis, Gail D, Higgins, Brian, Pisacane, Paul I, Lofgren, Julie A, Tindell, Charles, Evans, Douglas P, Maiese, Krista, Scher, Howard I, Sliwkowski, Mark X·2002·Cancer Cell

DOI 10.1016/s1535-6108(02)00097-1

Open this paper in CoChat — free account Open PDF

Abstract

ErbB2 is a ligand-less member of the ErbB receptor family that functions as a coreceptor with EGFR, ErbB3, and ErbB4. Here, we describe an approach to target ErbB2's role as a coreceptor using a monoclonal antibody, 2C4, which sterically hinders ErbB2's recruitment into ErbB ligand complexes. Inhibition of ligand-dependent ErbB2 signaling by 2C4 occurs in both low- and high-ErbB2-expressing systems. Since the ErbB3 receptor contains an inactive tyrosine kinase domain, 2C4 is very effective in blocking heregulin-mediated ErbB3-ErbB2 signaling. We demonstrate that the in vitro and in vivo growth of several breast and prostate tumor models is inhibited by 2C4 treatment.

Integrity signals

Registry

Crossref · 10.1016/s1535-6108(02)00097-1

Cites

73 of 73 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Self-citation
Real time quantitative PCR.Preprint
Heid, C., Stevens, J., Livak, K. J., & Williams, P. (1996) · Genome Research · doi:10.1101/gr.6.10.986 · Cited by 6,180
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
Cobleigh, M., Vogel, C. L., Tripathy, D., Robert, N. J., Scholl, S., Fehrenbacher, L., Wolter, J. M., Paton, V. E., Shak, S., Lieberman, G., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2639 · Cited by 2,767
A novel method for real time quantitative RT-PCR.Preprint
Gibson, U. E., Heid, C., & Williams, P. M. (1996) · Genome Research · doi:10.1101/gr.6.10.995 · Cited by 2,090
ErbB‐2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling
Graus-Porta, D., Beerli, R. R., Daly, J. M., & Hynes, N. E. (1997) · The EMBO Journal · doi:10.1093/emboj/16.7.1647 · Cited by 1,617
The EGF receptor family as targets for cancer therapy
Mendelsohn, J. M., & Baselga, J. M. (2000) · Oncogene · doi:10.1038/sj.onc.1204082 · Cited by 1,341
Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies
Hidalgo, M., Siu, L. L., Nemunaitis, J., Rizzo, J., Hammond, L. A., Takimoto, C., Eckhardt, S. G., Tolcher, A., Britten, C. D., Denis, L., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3267 · Cited by 1,001

Show all 83 references

Research works printed but not linked: 6

Agus, 1999, Prostate cancer cell cycle regulators, J. Natl. Cancer Inst., 91, 1869, 10.1093/jnci/91.21.1869 · DOI
Lewis, 1996, Growth regulation of human breast and ovarian tumor cells by heregulin, Cancer Res., 56, 1457
Nagabhushan, 1996, CWR22, Cancer Res., 56, 3042
Pinkas-Kramarski, 1996, Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions, EMBO J., 15, 2452, 10.1002/j.1460-2075.1996.tb00603.x · DOI
Tzahar, 1998, The ErbB-2/HER2 oncogenic receptor of adenocarcinomas, Biochim. Biophys. Acta, 1377, M25
Wainstein, 1994, CWR22, Cancer Res., 54, 6049

Sorted by citations

Items 601–700 of 874

Association of Tobacco Use, Alcohol Consumption and HER2 Polymorphisms With Response to Trastuzumab in HER2-Positive Breast Cancer Patients
Furrer, D., Jacob, S., Michaud, A., Provencher, L., Lemieux, J., & Diorio, C. (2017) · Clinical Breast Cancer · doi:10.1016/j.clbc.2017.11.012 · Cited by 11
Targeted therapies for prostate cancer
Asatiani, E., & Gelmann, E. P. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.2.283 · Cited by 11
Immunology and Immunotherapy
Cheung, N. V., & Sondel, P. M. (2005) · Springer eBooks · doi:10.1007/3-540-26616-x_14 · Cited by 11
Kinase signalling adaptation supports dysfunctional mitochondria in disease
Skalka, G., Tsakovska, M., & Murphy, D. J. (2024) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2024.1354682 · Cited by 12
Lhx3 is required to maintain cancer cell development of high-grade oligodendroglioma
Liu, H., Liu, W., Zhu, B., Xu, Q., Ni, X., & Yu, J. M. (2014) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-014-2209-x · Cited by 10
Primary squamous cell carcinoma of the breast: report of two cases with HER2 overexpression
Lei, R., & Miao, L. (2020) · Cancer Biology & Therapy · doi:10.1080/15384047.2020.1838033 · Cited by 10
Inactivating Amplified HER2: Challenges, Dilemmas, and Future Directions
Moasser, M. M. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-1121 · Cited by 9
Antitumor activities against breast cancers by an afucosylated anti‐HER2 monoclonal antibody H2Mab‐77‐mG2a ‐f
Tanaka, T., Suzuki, H., Ohishi, T., Kaneko, M. K., & Kato, Y. (2023) · Cancer Science · doi:10.1111/cas.16008 · Cited by 9
Efficacy and safety of neoadjuvant chemotherapy with concurrent liposomal-encapsulated doxorubicin, paclitaxel and trastuzumab for human epidermal growth factor receptor 2-positive breast cancer in clinical practice
Gavilá, J., Guerrero, Á., Climent, M. Á., Fernández-Martínez, A., Gozalbo, F., Carrascosa, M., Camps, J., Guillém, V., & Ruı́z, A. (2014) · International Journal of Clinical Oncology · doi:10.1007/s10147-014-0727-x · Cited by 10
Analysis of HER Family (HER1-4) Expression as a Biomarker in Combination Therapy with Pertuzumab, Trastuzumab and Docetaxel for Advanced HER2-positive Breast Cancer
Takada, K., Kashiwagi, S., Goto, W., Asano, Y., Morisaki, T., Fujita, H., Takashima, T., Ohsawa, M., Hirakawa, K., & Ohira, M. (2018) · Anticancer Research · doi:10.21873/anticanres.12473 · Cited by 10
Pharmacokinetic and exploratory exposure–response analysis of pertuzumab in patients with operable HER2-positive early breast cancer in the APHINITY study
Kirschbrown, W. P., Kågedal, M., Wang, B., Lindbom, L., Knott, A., Mack, R., Monemi, S., Nijem, I., Girish, S., Freeman, C., et al. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03826-1 · Cited by 10
Immunological Approaches in the Treatment of Metastasized Breast Cancer
Müller, V., Witzel, I., & Stickeler, E. (2009) · Breast Care · doi:10.1159/000262454 · Cited by 10
Stability of the recombinant anti-erbB2 scFv-Fc-interleukin-2 fusion protein and its inhibition of HER2-overexpressing tumor cells
DU, Y.-J., Lin, Z., ZHAO, Y.-H., FENG, X.-P., WANG, C.-Q., Wang, G., WANG, C.-D., Shi, W., Zuo, J., Li, F., et al. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1747 · Cited by 10
LMO1 is a novel oncogene in colorectal cancer and its overexpression is a new predictive marker for anti-EGFR therapy
Liu, J., Yan, P., Jing, N., & Yang, J. (2014) · Tumor Biology · doi:10.1007/s13277-014-2066-y · Cited by 10
Recent advances in the design and discovery of small-molecule therapeutics targeting HER2/neu
Dayam, R., Grande, F., Al‐Mawsawi, L. Q., & Neamati, N. (2007) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.17.1.83 · Cited by 10
One agonist and two receptors mediating the same effect: histamine receptors linked to adenylate cyclase in the brain.
Hough, L. B., Weinstein, H., & Green, J. P. (1980) · PubMed · Cited by 10
Development of Bispecific Molecules for the In Situ Detection of Protein-Protein Interactions and Protein Phosphorylation
van Dieck, J., Schmid, V., Heindl, D., Dziadek, S., Schräml, M., Gerg, M., Massoner, P., Engel, A. M., Tiefenthaler, G., Vural, S., et al. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.12.018 · Cited by 9
Transautocrine Signaling by Membrane Neuregulins Requires Cell Surface Targeting, Which Is Controlled by Multiple Domains
Montero, J. C., Barrueco, R. R., & Pandiella, A. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.190835 · Cited by 9
GNL3 and PA2G4 as Prognostic Biomarkers in Prostate Cancer
Kumar, S., Shuaib, M., Alasmari, A. F., Alqahtani, F., & Gupta, S. (2023) · Cancers · doi:10.3390/cancers15102723 · Cited by 9
Trastuzumab-resistant breast cancer cells-derived tumor xenograft models exhibit distinct sensitivity to lapatinib treatment in vivo
Liu, H., Ruan, S., Larsen, M. E., Tan, C., Liu, B., & Lyu, H. (2023) · Biological Procedures Online · doi:10.1186/s12575-023-00212-3 · Cited by 9
Bevacizumab confers additional advantage to the combination of trastuzumab plus pertuzumab in trastuzumab-refractory breast cancer model
Sun, Y., Dey, N., Brammer, M. G., De, P. K., & Leyland-Jones, B. R. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2233-7 · Cited by 9
Rifaximin for Pertuzumab-Related GI Toxicities
Soyano, A. E., Reynolds, G. A., Moreno‐Aspitia, A., & Chumsri, S. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00168 · Cited by 9
Synchronous and Metachronous Metastatic Breast Cancer, with Different Histology and Opposite Immunophenotype, Treated with Combination of Chemotherapy, Anti-Her2, and Endocrine Therapy: A Case Report
Megaro, G., Rossi, L., Ceddia, S., Sinjari, M., Mannino, A., Gozzi, E., Cosimati, A., Brandi, M., Bitca, V., Toscani, I., et al. (2020) · Case Reports in Oncology · doi:10.1159/000507433 · Cited by 9
Monoclonal Antibodies, Small Molecule Inhibitors and Antibody-drug Conjugates as HER2 Inhibitors
Li, X., Liu, C., & Rao, G. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200908112847 · Cited by 10
Targeted Agents for HER2-Positive Breast Cancer: Optimal Use in Older Patients
Singh, J. C., & Lichtman, S. M. (2015) · Drugs & Aging · doi:10.1007/s40266-015-0326-1 · Cited by 9
Sensitization of chemotherapy by anti-HER
Kataoka, A., Ishida, M., Murakami, S., & Ohno, S. (2004) · Breast Cancer · doi:10.1007/bf02968288 · Cited by 9
Targeting ERBB Receptors in Cancer
Hynes, N. E. (2007) · Springer eBooks · doi:10.1007/978-3-540-31209-3_4 · Cited by 9
Prostate Cancer Review.
Kim, E. H., & Andriole, G. L. (2018) · Europe PMC (PubMed Central) · Cited by 8
Frequency and Nature of Genomic Alterations in ERBB2-Altered Urothelial Bladder Cancer
Leary, J. B., Enright, T. J., Bakaloudi, D. R., Basnet, A., Bratslavsky, G., Jacob, J. M., Spiess, P. E., Li, R., Necchi, A., Kamat, A. M., et al. (2024) · Targeted Oncology · doi:10.1007/s11523-024-01056-x · Cited by 9
Functional genomic characterization of a synthetic anti-HER3 antibody reveals a role for ubiquitination by RNF41 in the anti-proliferative response
Turowec, J. P., Lau, E. W. T., Wang, X., Brown, K. R., Fellouse, F. A., Jawanda, K. K., Pan, J., Moffat, J., & Sidhu, S. S. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.004420 · Cited by 8
Clinical Trial Outcomes
Martinez, R. (2019) · JACC Heart Failure · doi:10.1016/j.jchf.2018.12.003 · Cited by 8
Neu Perspectives, Therapies, and Challenges for Metastatic HER2-Positive Breast Cancer
Salkeni, M. A., Rizvi, W., Hein, K. Z., & Higa, G. M. (2021) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s288344 · Cited by 9
Production and Characterization of New Anti-HER2 Monoclonal Antibodies
Mahdavi, M., Keyhanfar, M., Jafarian‐Dehkordi, A., Mohabatkar, H., & Rabbani, M. (2015) · Monoclonal Antibodies in Immunodiagnosis and Immunotherapy · doi:10.1089/mab.2014.0092 · Cited by 8
Oligoclonal antibodies to target the ErbB family
D’Souza, J. W., & Robinson, M. K. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1042362 · Cited by 8
EGFR family heterodimers in cancer pathogenesis and treatment
Stern, H. M. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-356-1_2 · Cited by 8
Pertuzumab for the treatment of metastatic breast cancer
Langdon, S. P., & Cameron, D. (2013) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2013.814419 · Cited by 8
Anti-HER3 Monoclonal Antibody Inhibits Acquired Trastuzumab-Resistant Gynecologic Cancers
Li, X., Duan, Y., Qiao, C., Zhou, T., Yu, M., Geng, J., Feng, J., Shen, B., Lv, M., & Li, Y. (2015) · Technology in Cancer Research & Treatment · doi:10.1177/1533034615588422 · Cited by 8
Bioterapia: aplicaciones actuales y futuras en oncología
Prat, A., & Baselga, J. (2007) · Medicina Clínica · doi:10.1157/13107796 · Cited by 8
Combination epidermal growth factor receptor inhibition and radical radiotherapy for NSCLC
Rogers, S. J., Harrington, K. J., Eccles, S. A., & Nutting, C. M. (2004) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.4.4.569 · Cited by 8
Conformational diversity and protein–protein interfaces in drug repurposing in Ras signaling pathway
Sayin, A. Z., Abali, Z., Senyuz, S., Cankara, F., Gürsoy, A., & Keskin, Ö. (2024) · Scientific Reports · doi:10.1038/s41598-023-50913-8 · Cited by 7
HER2-Positive Early Breast Cancer: Time for Ultimate De-Escalation?
Tauber, N., Cirkel, C., Claussen, A., Fick, F., Kontomanolis, E. N., Krawczyk, N., Rody, A., & Banys‐Paluchowski, M. (2024) · Cancers · doi:10.3390/cancers16061121 · Cited by 9
New Frontiers in the Treatment of Patients with HER2+ Cancer and Brain Metastases: Is Radiotherapy Always Useful?
Scandurra, G., Lombardo, V., Scibilia, G., Sambataro, D., Gebbia, V., Scollo, P., Pecorino, B., & Valerio, M. R. (2024) · Cancers · doi:10.3390/cancers16132466 · Cited by 7
Monoclonal Antobodies: Application in Radiopharmacy
Ligiero, T. B., Albernaz, M. D. S., de Carvalho, S., de Oliveira, S. V., & Santos‐Oliveira, R. (2014) · Current Radiopharmaceuticals · doi:10.2174/1874471006666131119212015 · Cited by 7
Novel quinazoline derivatives exhibit antitumor activity by inhibiting JAK2/STAT3
Qiao, H., Zhao, D., Shi, H., Ren, K., Li, J., & Li, E. (2015) · Oncology Reports · doi:10.3892/or.2015.4140 · Cited by 7
Bispecific Antibodies Progression in Malignant Melanoma
Tang, J., Gong, Y.-L., & Ma, X.-L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.837889 · Cited by 6
Cancer Immunotherapy: More Is (Much) Better
Yarden, Y., & Sela, M. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0996 · Cited by 7
Novel therapeutics in breast cancer—Looking to the future
Vora, T. S., de Azambuja, E., Awada, A. H., & Piccart, M. J. (2009) · Update on Cancer Therapeutics · doi:10.1016/j.uct.2009.07.001 · Cited by 7
Emerging drugs in metastatic breast cancer
Dızdar, Ö., & Altundağ, K. (2009) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210802625671 · Cited by 7
Chemotherapy-related cardiotoxicity
Aggarwal, S., Kamboj, J., & Arora, R. R. (2013) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944712474332 · Cited by 7
Enhancement of paclitaxel-induced apoptosis in HER2-overexpressing human breast cancer cells by a pertuzumab mimetic peptide, HRAP
Nakajima, H., Mizuta, N., Sakaguchi, K., Fujiwara, I., Yoshimori, A., Magae, J., & Tanuma, S. (2010) · Journal of Bioscience and Bioengineering · doi:10.1016/j.jbiosc.2010.02.007 · Cited by 7
HER2/neu: an increasingly important therapeutic target. Part 1: basic biology & therapeutic armamentarium
Nelson, E. L. (2014) · Clinical Investigation · doi:10.4155/cli.14.57 · Cited by 7
Use of computational and recombinant technologies for developing novel influenza vaccines
Wong, T. M., & Ross, T. M. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2016.1113877 · Cited by 7
Combination efficacy of pertuzumab and trastuzumab for trastuzumab emtansine-resistant cells exhibiting attenuated lysosomal trafficking or efflux pumps upregulation
Yamashita‐Kashima, Y., Shu, S., Osada, M., Fujimura, T., Yoshiura, S., Harada, N., & Yoshimura, Y. (2020) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-020-04138-5 · Cited by 7
Anti-IGF-1R monoclonal antibody inhibits the carcinogenicity activity of acquired trastuzumab-resistant SKOV3
Wang, W., Zhang, Y., Lv, M., Feng, J., Peng, H., Geng, J., Zhou, L., Zhou, T., Li, X., Shen, B., et al. (2014) · Journal of Ovarian Research · doi:10.1186/s13048-014-0103-5 · Cited by 7
Roles of androgen-dependent and -independent activation of signal transduction pathways for cell proliferation of prostate cancer cells
Inoue, T., Kobayashi, T., Terada, N., Shimizu, Y., Kamoto, T., Ogawa, O., & Nakamura, E. (2007) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2.5.689 · Cited by 9
Current Status of Signal Transduction Modulators in the Treatment of Gynecologic Malignancies
Ashouri, S., & García, A. A. (2007) · Current Treatment Options in Oncology · doi:10.1007/s11864-007-0051-z · Cited by 7
Epidermal growth factor receptor pathway inhibitors
Baselga, J. M. (2006) · Update on Cancer Therapeutics · doi:10.1016/j.uct.2006.08.002 · Cited by 7
Targeting Human Epidermal Growth Factor Receptor 2: It Is Time to Kill Kinase Death Human Epidermal Growth Factor Receptor 3
Menéndez, J. A., & Lupu, R. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.0395 · Cited by 7
CHRONIC FISTULA OF THE MANDIBLE.
NEWBY, J. D., & AITKEN, W. J. (1964) · PubMed Central · Cited by 7
HER2/neu as a Signaling and Therapeutic Marker in Uterine Serous Carcinoma
Ettorre, V. M., Palmieri, L., Clemente, V., & Santin, A. D. (2025) · Cells · doi:10.3390/cells14161282 · Cited by 6
Leveraging HER2-targeted biparatopic antibodies in solid tumors
Liu, X., Fan, X., Gao, X., Hu, W., & Sun, P. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107687 · Cited by 6
BiDAC-dependent degradation of plasma membrane proteins by the endolysosomal system
Villa, S., Jafri, Q., Lazzari-Dean, J. R., Sangha, M., Olsson, N., Lefebvre, A. E. Y. T., Fitzgerald, M. E., Jackson, K. L., Chen, Z., Feng, B. Y., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59627-z · Cited by 6
The ErbB3-binding protein EBP1 modulates lapatinib sensitivity in prostate cancer cells
Awasthi, S., Ezelle, H. J., Hassel, B. A., & Hamburger, A. W. (2015) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-015-2409-z · Cited by 6
Are there benefits in routine clinical practice of continuing trastuzumab after progression for metastatic breast cancer patients?
Espósito, A., Munzone, E., Bagnardi, V., Adamoli, L., Sciandivasci, A., Cullurà, D., Goldhirsch, A., & Nolè, F. (2012) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32835679d3 · Cited by 6
Pertuzumab in human epidermal growth-factor receptor 2-positive breast cancer: clinical and economic considerations
Younis, T., & Lamond, N. W. D. (2014) · International Journal of Women s Health · doi:10.2147/ijwh.s47357 · Cited by 6
PR status is a more decisive factor in efficacy of adding pertuzumab into neoadjuvant therapy for HER2-positive and lymph node-positive breast cancer than ER status: a real-world retrospective study in China
Liu, X., Liu, Z., Li, C., Song, X., Wang, X., Li, S., & Yu, Z. (2023) · World Journal of Surgical Oncology · doi:10.1186/s12957-023-03178-4 · Cited by 6
Prognostic impact of HER2 biomarker levels in trastuzumab-treated early HER2-positive breast cancer
Rönnlund, C., Sifakis, E. G., Schagerholm, C., Yang, Q., Karlsson, E., Chen, X., Foukakis, T., Weidler, J. M., Bates, M., Fredriksson, I., et al. (2024) · Breast Cancer Research · doi:10.1186/s13058-024-01779-9 · Cited by 6
HER-2/neu Cancer Vaccines: Present Status and Future Prospects
Kaumaya, P. T. P. (2006) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-005-9000-5 · Cited by 6
Targeted Agents in Ovarian Cancer
Kristedja, T., Morgan, R., & Cristea, M. C. (2010) · Women s Health · doi:10.2217/whe.10.48 · Cited by 7
Immunology and Immunotherapy of Ovarian Cancer
Wilczyński, J. R., & Nowak, M. (2015) · Springer eBooks · doi:10.1007/978-3-662-46410-6_22 · Cited by 6
The Anti-HER2 Monoclonal Antibody Pertuzumab May Be Effective in Androgen-Independent Prostate Cancer
DeGrendele, H. C., & Jain, V. K. (2003) · Clinical Prostate Cancer · doi:10.1016/s1540-0352(11)70034-8 · Cited by 6
Pari passu dimers of dimers
Sliwkowski, M. X. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1209959109 · Cited by 5
Self-citation
Marriage of antibody–drug conjugate with gold nanorods to achieve multi-modal ablation of breast cancer cells and enhanced photoacoustic performance
Cao, F., Yao, Q., Yang, T., Zhang, Z., Han, Y., Feng, J., & Wang, X. (2016) · RSC Advances · doi:10.1039/c6ra01557c · Cited by 5
Targeting HER2 by monoclonal antibodies for cancer therapy
Hasmann (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-397176-0.00009-1 · Cited by 5
A randomized, double-blind, single-dose, single-center, parallel phase I clinical study comparing the pharmacokinetics, immunogenicity, safety, and tolerance of pertuzumab injection and Perjeta® in healthy Chinese male subjects
Liu, G., Xu, Z., Yang, W., Xue, J., Wang, Y., Liu, Z., Cui, Y., Qu, X., Chang, T., Yu, S., et al. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1988567 · Cited by 5
Innovative Therapeutic Approaches for Patients with HER2-Positive Breast Cancer
Salimbeni, B. T., Ferraro, E., Bielo, L. B., & Curigliano, G. (2023) · Cancer treatment and research · doi:10.1007/978-3-031-33602-7_10 · Cited by 5
A Cell-Penetrating Peptide Improves Anti-HER2 Single-Chain Variable Fragment Internalization and Antitumor Activity against HER2-Positive Breast Cancer In Vitro and In Vivo
Li, J., Zhou, Y., Su, Z., Li, X., Zhang, L., & Li, S. (2024) · Molecules · doi:10.3390/molecules29061247 · Cited by 5
Targeted therapies in breast cancer
Hynes, N. E., & MacDonald, G. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139046947.054 · Cited by 5
Antibody-Mediated Receptor Endocytosis: Harnessing the Cellular Machinery to Combat Cancer
Tarcic, G., & Yarden, Y. (2013) · Springer eBooks · doi:10.1007/978-1-4614-6528-7_17 · Cited by 6
Diagnostic and Therapeutic Implications of Histone Epigenetic Modulators in Breast Cancer
Walsh, L., Gallagher, W. M., O’Connor, D. P., & Chonghaile, T. N. (2016) · Expert Review of Molecular Diagnostics · doi:10.1586/14737159.2016.1156534 · Cited by 5
Therapeutic Antibodies and Immunologic Conjugates
Cheung, N. V. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-2865-7.00032-1 · Cited by 5
Therapeutic and Mechanistic Perspectives of Protein Complexes in Breast Cancer
Waterhouse, M. P., Ugur, R., & Khaled, W. T. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00335 · Cited by 5
A novel rabbit derived anti-HER2 antibody with pronounced therapeutic effectiveness on HER2-positive breast cancer cells in vitro and in humanized tumor mice (HTM)
Wege, A. K., Kirchhammer, N., Kazandjian, L. V., Prassl, S., Brandt, M., Piendl, G., Ortmann, O., Fischer, S., & Brockhoff, G. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02484-9 · Cited by 5
HER2 copy number quantification in primary tumor and cell-free DNA provides additional prognostic information in HER2 positive early breast cancer
Chen, X., Lin, Y., Jiang, Z., Li, Y., Zhang, Y., Wang, Y., Yu, F., Guo, W., Chen, L., Chen, M., et al. (2022) · The Breast · doi:10.1016/j.breast.2022.02.002 · Cited by 6
Neuregulin 4 Boosts the Efficacy of Anti-ERBB2 Neutralizing Antibodies
Miano, C., Romaniello, D., Mazzeschi, M., Morselli, A., Pra, S. D., Sacchi, F., Bongiovanni, C., Sgarzi, M., Pantano, E., Lauriola, M., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.831105 · Cited by 5
ErbB2/HER2: Its Contribution to Basic Cancer Biology and the Development of Molecular Targeted Therapy
Yamamoto, T. S., Saito, M., Kumazawa, K., Doi, A., Matsui, A., Takebe, S., Amari, T., Oyama, M., & Semb, K. A. (2011) · InTech eBooks · doi:10.5772/21965 · Cited by 4
Signal Transduction Pathways in Breast Cancer – Drug Targets and Challenges
Azab, S. S., & Al-Hendy, A. A. (2011) · InTech eBooks · doi:10.5772/23855 · Cited by 5
Strategies and methodologies for identifying molecular targets in sarcomas and other tumors
Ravi, V., & Wong, M. K. K. (2005) · Current Treatment Options in Oncology · doi:10.1007/s11864-005-0027-9 · Cited by 5
Growth Factor and Signaling Networks
De, P. K. R., Dey, N., & Leyland-Jones, B. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-374984-0.00664-1 · Cited by 5
Semaphorin 3F inhibits breast cancer metastasis by regulating the Akt-mTOR and TGFβ signaling pathways via neuropilin-2
Nakayama, H., Murakami, A., Nishida‐Fukuda, H., Fukuda, S., Matsugi, E., Nakahara, M., Kusumoto, C., Kamei, Y., & Higashiyama, S. (2025) · Scientific Reports · doi:10.1038/s41598-025-91559-y · Cited by 4
Structural analysis of HER2-trastuzumab complex reveals receptor conformational adaptation
Vacca, S., Gragera, M., Buschiazzo, A., Herreros, D., Krieger, J., Bonn-Garcia, S., Melero, R., Sorzano, C. Ó. S., Carazo, J. M., Medalia, O., et al. (2025) · Science Advances · doi:10.1126/sciadv.adu9945 · Cited by 5
Targeted Agents for HER2-Positive Breast Cancer: Optimal Use in Older Patients
Singh, J. C., & Lichtman, S. M. (2021) · Drugs & Aging · doi:10.1007/s40266-021-00889-9 · Cited by 5
HER2 Expression in Peritoneal Dissemination of High-Grade Serous Ovarian Carcinoma: A Comparative Study of Immunohistochemical Reactivity Using Four HER2 Antibodies
Yeo, M., Kim, S., Yoo, H. J., Suh, K., & Kim, K. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11236963 · Cited by 4
Response of Therapy in Cell-Cycle Regulatory Genes in Breast Cancer
Mir, M. A., Aisha, S., Fatima, K., & Malik, F. A. (2023) · Springer eBooks · doi:10.1007/978-981-19-8911-7_16 · Cited by 4
Effects of a human compact anti-ErbB2 antibody on prostate cancer
Lorenzo, C. D. (2012) · Oncology Reports · doi:10.3892/or.2012.1760 · Cited by 4
A bispecific anti-ErbB2 antibody potently induces ErbB2 internalization and suppresses ErbB2-overexpressing tumor growth
Zhang, Y., Wang, L., Chong, X., Yu, X., Meng, Y., Dong, J., Wang, C., Wang, H., Yang, Y., Xia, T., et al. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.06.131 · Cited by 4
Biomarker-driven targeted therapies for gastric/gastro-esophageal junction malignancies
Kim, S., Barzi, A., & Rajdev, L. N. (2018) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.03.001 · Cited by 4
Novel Therapies to Overcome HER2 Therapy Resistance in Breast Cancer
Nahta, R. (2019) · Resistance to targeted anti-cancer therapeutics · doi:10.1007/978-3-030-21477-7_7 · Cited by 3
Negative regulation of signaling by the EGFR family
Carraway, K. L., Yen, L., Ingalla, E., & Sweeney, C. A. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-356-1_12 · Cited by 4
Novel pharmacological approaches in the treatment of breast cancer
Nahta, R., Hortobágyi, G. N., & Esteva, F. J. (2003) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.12.6.909 · Cited by 4

Authors: Agus, D. B., Akita, R. W., Fox, W. D., Lewis, G. D., Higgins, B., Pisacane, P. I., Lofgren, J. A., Tindell, C., Evans, D. P., Maiese, K., Scher, H. I., & Sliwkowski, M. X.
Affiliations: Cedars-Sinai Medical Center (US)
Genentech (US)
Memorial Sloan Kettering Cancer Center (US)
Corresponding author: Sliwkowski, Mark X
ORCID: Agus, David B
Scher, Howard I
Sliwkowski, Mark X
Venue: Cancer Cell
Publisher: Elsevier BV
Published: 2002-08
Volume: 2
Issue: 2
Pages: 127-137
ISSN: 1535-6108 (ISSN-L)
DOI: 10.1016/s1535-6108(02)00097-1
OpenAlex: W2014457594
Cited by: 873
References: 83
Citations by year: 2026: 2 · 2025: 10 · 2024: 21 · 2023: 38 · 2022: 21 · 2021: 21 · 2020: 28 · 2019: 29 · 2018: 27 · 2017: 24 · 2016: 38 · 2015: 48 · 2014: 69 · 2013: 59 · 2012: 51
FWCI: 16.85
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 4003 d)
Locations: Cancer Cell (publishedVersion)
PubMed (publishedVersion)
Funders: PepsiCo
Topics: Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
Keywords: ERBB2, HER2, HER3, neuregulin-1, ErbB receptor family, breast cancer, prostate cancer, tumor growth inhibition, tyrosine kinase inhibitors
MeSH terms: Androgens, Animals, Antibodies, Monoclonal, Antineoplastic Agents, Breast Neoplasms, Cell Division, Female, Humans, Ligands, Male, Neoplasm Transplantation, Prostatic Neoplasms, Protein Binding, RNA, Messenger, Time Factors, Transplantation, Heterologous, Tumor Cells, Cultured, Signal Transduction, Gene Expression Regulation, Neoplastic, Erb-b2 Receptor Tyrosine Kinases, Neuregulin-1, Receptor, ErbB-3, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks